Other analysts have also issued reports about the stock. BTIG Research decreased their price target on shares of Delcath Systems to $19.00 in a research report on Tuesday, November 15th. HC Wainwright decreased their price objective on shares of Delcath Systems from $25.00 to $19.00 and set a buy rating for the company in a research report on Wednesday, August 10th.
Delcath Systems Trading Down 1.4 %
Shares of DCTH opened at $2.92 on Monday. Delcath Systems has a twelve month low of $2.34 and a twelve month high of $10.24. The company has a market cap of $25.11 million, a P/E ratio of -0.77 and a beta of 0.92. The company has a current ratio of 1.28, a quick ratio of 1.15 and a debt-to-equity ratio of 2.55. The company’s fifty day simple moving average is $3.03 and its 200-day simple moving average is $3.82.
Institutional Investors Weigh In On Delcath Systems
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Delcath Systems by 5.7% in the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after acquiring an additional 19,605 shares during the period. Cibc World Market Inc. boosted its stake in Delcath Systems by 4.0% during the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after purchasing an additional 3,432 shares during the last quarter. CI Investments Inc. purchased a new position in shares of Delcath Systems during the 1st quarter worth $559,000. Dimensional Fund Advisors LP purchased a new position in shares of Delcath Systems during the 1st quarter worth $75,000. Finally, Millennium Management LLC purchased a new position in shares of Delcath Systems during the 2nd quarter worth $40,000. Institutional investors and hedge funds own 26.18% of the company’s stock.
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.